Y Hirota

No ORCID on file · 8 papers in corpus · active 1987-2021

Study types

  • article 5
  • other 2
  • paratext 1

Condition tags

  • mesh:D004715 4
  • endometriosis 4
  • endometrioma 2
  • adenomyosis 2
  • infertility 1
article 2021
SAGE open medicine ·doi:10.1177/20503121211005992

Objective: Long-term administration of dienogest, which is known to have effect on bone mineral density, is frequently done in patients with endometriosis and adenomyosis, but a few studies focused on the bone mineral density changes after …

paratext 2020
·doi:10.15574/hw.2020.148.

Ч и т а й т е н а с н а с а й т і w w w .m e d -e x p e r t .c o m .u a ЗДОРОВ'Я ЖІНКИ 2 (148)/2020 ЗАСНОВНИКИ НАЦІОНАЛЬНА МЕДИЧНА АКАДЕМІЯ ПІСЛЯДИПЛОМНОЇ ОСВІТИ імені П.Л.ШУПИКА (НМАПО імені П.Л.Шупика) ДЕРЖАВНА УСТАНОВА «ІНСТИТУТ ПЕДІАТРІ…

article 2012
·doi:10.1093/humrep/27.s2.78
article 2009
Human Reproduction ·doi:10.1093/humrep/dep297

BACKGROUND: The aim of this study was to evaluate the impact of post-operative oral contraceptives (OCs) use on the rate of recurrence after laparoscopic excision of ovarian endometrioma. METHODS: In May 2005, we introduced a 'post-operativ…

article 2006
Human Reproduction ·doi:10.1093/humrep/del125

BACKGROUND: To analyse risk factors that influence the recurrence of endometrioma after laparoscopic excision. METHODS: A total of 224 patients who had a minimum of 2 years of post-operative follow-up after laparoscopic ovarian endometrioma…

article 2002
·doi:10.1016/s0015-0282(02)02983-7
other 1987
Nihon Sanka Fujinka Gakkai zasshi ·doi:10.1007/978-1-4613-1717-3_58

To overcome the dose limiting toxicity of cisplatin we administered high-dose (12 mg/kg) cisplatin together with hypertonic (3%) saline to tumor-bearing nude mice three times at four day intervals. The heterotransplanted human ovarian tumor…

other 1987
Nihon Sanka Fujinka Gakkai zasshi

Experimental chemotherapy was performed using the human tumor-nude mouse system. The tumors were mucinous cystadenocarcinoma (OVA-1), undifferentiated carcinoma (OVA-2), endometrioid adenocarcinoma (OVA-3), serous cystadenocarcinoma (OVA-4)…